Working… Menu

BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03083691
Recruitment Status : Enrolling by invitation
First Posted : March 20, 2017
Last Update Posted : November 13, 2020
Bristol-Myers Squibb
Information provided by (Responsible Party):
Lung Cancer Group Cologne

No Study Results Posted on for this Study
Recruitment Status : Enrolling by invitation
Estimated Primary Completion Date : December 2022
Estimated Study Completion Date : September 2023